Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Cash Flows from Operating Activities:          
Net income (loss)     $ 696,532 $ (453,098)  
Adjustments to reconcile net income (loss) to net cash used in operating activities:          
Change in fair value of warrant liability $ (1,070,750) $ (466,500) (3,189,500) (466,500)  
Transactions costs associated with the Initial Public Offering   837,355   837,355  
Interest earned on marketable securities held in Trust Account (3,473) (6,646) (10,306) (6,646)  
Changes in operating assets and liabilities:          
Prepaid expenses     75,822 (163,745)  
Accounts payable and accrued expenses     1,755,429 69,833  
Net cash used in operating activities     (672,023) (182,801)  
Cash Flows from Investing Activities:          
Investment of cash into Trust Account       (230,000,000)  
Cash withdrawn from Trust Account to pay franchise and income taxes     13,368    
Net cash provided by (used in) investing activities     13,368 (230,000,000)  
Cash Flows from Financing Activities:          
Proceeds from issuance of Class B common stock to Sponsor       25,000  
Proceeds from sale of Units, net of underwriting discounts paid       225,400,000  
Proceeds from sale of Private Placement Units       6,500,000  
Proceeds from promissory notes - related party       140,671  
Repayment of promissory note-related party       (140,671)  
Payment of offering costs     (5,450) (473,487)  
Net cash (used in) provided by financing activities     (5,450) 231,451,513  
Net Change in Cash     (664,105) 1,268,712  
Cash - Beginning     1,017,137 0 $ 0
Cash - Ending 353,032 1,268,712 353,032 1,268,712 1,017,137
Non-Cash investing and financing activities:          
Offering costs included in accrued offering costs       5,450  
Initial classification of Class A common stock subject to possible redemption       230,000,000  
Deferred underwriting fee payable $ 8,050,000 $ 8,050,000 $ 8,050,000 $ 8,050,000 $ 8,050,000